WO2003013571A1 - Peptidomimetics of biologically active metallopeptides - Google Patents
Peptidomimetics of biologically active metallopeptides Download PDFInfo
- Publication number
- WO2003013571A1 WO2003013571A1 PCT/US2002/025574 US0225574W WO03013571A1 WO 2003013571 A1 WO2003013571 A1 WO 2003013571A1 US 0225574 W US0225574 W US 0225574W WO 03013571 A1 WO03013571 A1 WO 03013571A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- peptidomimetic
- metallopeptide
- phe
- biologically active
- Prior art date
Links
- 0 *C1CC(*)C(*)C1 Chemical compound *C1CC(*)C(*)C1 0.000 description 10
- CJFYRIGZUUSDRP-CABCVRRESA-N CN(C[C@@H](C1)OCc2ccccc2)[C@@H]1C(NCCCN)=O Chemical compound CN(C[C@@H](C1)OCc2ccccc2)[C@@H]1C(NCCCN)=O CJFYRIGZUUSDRP-CABCVRRESA-N 0.000 description 3
- SZMQCAOWTUUKDG-NSHDSACASA-N CC([C@@H]1NCCc2c1cccc2)=O Chemical compound CC([C@@H]1NCCc2c1cccc2)=O SZMQCAOWTUUKDG-NSHDSACASA-N 0.000 description 1
- BNOGOCURMIFIFD-LLVKDONJSA-N CC([C@@H]1NCc2ccccc2C1)=O Chemical compound CC([C@@H]1NCc2ccccc2C1)=O BNOGOCURMIFIFD-LLVKDONJSA-N 0.000 description 1
- SZMQCAOWTUUKDG-LLVKDONJSA-N CC([C@H]1NCCc2ccccc12)=O Chemical compound CC([C@H]1NCCc2ccccc12)=O SZMQCAOWTUUKDG-LLVKDONJSA-N 0.000 description 1
- BNOGOCURMIFIFD-NSHDSACASA-N CC([C@H]1NCc2ccccc2C1)=O Chemical compound CC([C@H]1NCc2ccccc2C1)=O BNOGOCURMIFIFD-NSHDSACASA-N 0.000 description 1
- IIRQXSHHGLUWHF-UHFFFAOYSA-N CC1N=CC=CN1 Chemical compound CC1N=CC=CN1 IIRQXSHHGLUWHF-UHFFFAOYSA-N 0.000 description 1
- IDGHYDUKILPPNG-UHFFFAOYSA-N CCCCCNC(c(cc1)ccc1O)=O Chemical compound CCCCCNC(c(cc1)ccc1O)=O IDGHYDUKILPPNG-UHFFFAOYSA-N 0.000 description 1
- LZDRLYMZVCFDSN-UHFFFAOYSA-N CCCCCNC(c1ccccc1)=O Chemical compound CCCCCNC(c1ccccc1)=O LZDRLYMZVCFDSN-UHFFFAOYSA-N 0.000 description 1
- JDCDOJMYHQCEQZ-UHFFFAOYSA-N CCCCCNC(c1cccnc1)=O Chemical compound CCCCCNC(c1cccnc1)=O JDCDOJMYHQCEQZ-UHFFFAOYSA-N 0.000 description 1
- UEXFDEKTELCPNF-UHFFFAOYSA-N CCCOc1cc2ccccc2cc1 Chemical compound CCCOc1cc2ccccc2cc1 UEXFDEKTELCPNF-UHFFFAOYSA-N 0.000 description 1
- AQVGZQVTDKSOAR-LLQWEQGGSA-N CN(CC(C1)N2C[C@H]1Oc1cc(cccc3)c3cc1)[C@@H](CCCCN)C2=O Chemical compound CN(CC(C1)N2C[C@H]1Oc1cc(cccc3)c3cc1)[C@@H](CCCCN)C2=O AQVGZQVTDKSOAR-LLQWEQGGSA-N 0.000 description 1
- VRJROVWSSWDBLU-CVEARBPZSA-N CN(C[C@@H](C1)OCc2ccccc2)[C@@H]1C(NCCCCN)=O Chemical compound CN(C[C@@H](C1)OCc2ccccc2)[C@@H]1C(NCCCCN)=O VRJROVWSSWDBLU-CVEARBPZSA-N 0.000 description 1
- DWHMJKLSLRQBEY-NRFANRHFSA-N NC(NCCC[C@@H](C(N(CCc1cc2ccccc2cc1)CC1)=O)N1C1CC1)=O Chemical compound NC(NCCC[C@@H](C(N(CCc1cc2ccccc2cc1)CC1)=O)N1C1CC1)=O DWHMJKLSLRQBEY-NRFANRHFSA-N 0.000 description 1
- SOXALKOOANKAEB-UHFFFAOYSA-N OCCN1C(c2ccccc2)OCC1 Chemical compound OCCN1C(c2ccccc2)OCC1 SOXALKOOANKAEB-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N OCCNCCO Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02768507A EP1425029A4 (en) | 2001-08-10 | 2002-08-12 | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES |
JP2003518577A JP2005504043A (ja) | 2001-08-10 | 2002-08-12 | 生物学的に活性な金属ペプチド類のペプチド模倣体類 |
AU2002331064A AU2002331064B2 (en) | 2001-08-10 | 2002-08-12 | Peptidomimetics of biologically active metallopeptides |
CA002462200A CA2462200A1 (en) | 2001-08-10 | 2002-08-12 | Peptidomimetics of biologically active metallopeptides |
US10/762,079 US7354923B2 (en) | 2001-08-10 | 2004-01-21 | Piperazine melanocortin-specific compounds |
US10/761,889 US7326707B2 (en) | 2001-08-10 | 2004-01-21 | Bicyclic melanocortin-specific compounds |
US10/776,419 US7807678B2 (en) | 2001-08-10 | 2004-02-10 | Peptidomimetics of biologically active metallopeptides |
US10/776,657 US7189755B2 (en) | 2001-08-10 | 2004-02-10 | Pyrrolidine melanocortin-specific compounds |
US11/036,282 US7732451B2 (en) | 2001-08-10 | 2005-01-14 | Naphthalene-containing melanocortin receptor-specific small molecule |
US11/040,838 US7655658B2 (en) | 2001-08-10 | 2005-01-21 | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US11/099,814 US7718802B2 (en) | 2001-08-10 | 2005-04-05 | Substituted melanocortin receptor-specific piperazine compounds |
US11/680,932 US7601753B2 (en) | 2001-08-10 | 2007-03-01 | Pyrrolidine melanocortin-specific compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31140401P | 2001-08-10 | 2001-08-10 | |
US60/311,404 | 2001-08-10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/837,519 Continuation-In-Part US7456184B2 (en) | 2001-08-10 | 2004-04-30 | Melanocortin receptor-specific compounds |
Related Child Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10761889 Continuation-In-Part | 2003-01-17 | ||
US10762079 Continuation-In-Part | 2003-05-30 | ||
US10/762,079 Continuation-In-Part US7354923B2 (en) | 2001-08-10 | 2004-01-21 | Piperazine melanocortin-specific compounds |
US10/761,889 Continuation-In-Part US7326707B2 (en) | 2001-08-10 | 2004-01-21 | Bicyclic melanocortin-specific compounds |
US10/776,419 Continuation US7807678B2 (en) | 2001-08-10 | 2004-02-10 | Peptidomimetics of biologically active metallopeptides |
US10/776,657 Continuation-In-Part US7189755B2 (en) | 2001-08-10 | 2004-02-10 | Pyrrolidine melanocortin-specific compounds |
US11/036,282 Continuation-In-Part US7732451B2 (en) | 2001-08-10 | 2005-01-14 | Naphthalene-containing melanocortin receptor-specific small molecule |
US11/040,838 Continuation-In-Part US7655658B2 (en) | 2001-08-10 | 2005-01-21 | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US11/099,814 Continuation-In-Part US7718802B2 (en) | 2001-08-10 | 2005-04-05 | Substituted melanocortin receptor-specific piperazine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003013571A1 true WO2003013571A1 (en) | 2003-02-20 |
Family
ID=23206723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/025574 WO2003013571A1 (en) | 2001-08-10 | 2002-08-12 | Peptidomimetics of biologically active metallopeptides |
Country Status (6)
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004098602A1 (en) * | 2003-05-01 | 2004-11-18 | Palatin Technologies, Inc. | Melanocortin receptor-specific compounds |
WO2005079574A1 (en) * | 2004-01-21 | 2005-09-01 | Palatin Technologies, Inc. | Bicyclic melanocorin-specific compounds |
WO2005102340A1 (en) * | 2003-05-30 | 2005-11-03 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
US7026335B2 (en) | 2002-04-30 | 2006-04-11 | The Procter & Gamble Co. | Melanocortin receptor ligands |
US7132539B2 (en) | 2002-10-23 | 2006-11-07 | The Procter & Gamble Company | Melanocortin receptor ligands |
WO2008090357A2 (en) * | 2007-01-24 | 2008-07-31 | Palatin Technologies, Inc. | N, n; -substituted piperazines binding to melanocortin receptor |
WO2009105825A1 (en) | 2008-02-29 | 2009-09-03 | Mimetica Pty Ltd | 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
WO2009105823A1 (en) | 2008-02-29 | 2009-09-03 | Mimetica Pty Ltd | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
US7622496B2 (en) | 2005-12-23 | 2009-11-24 | Zealand Pharma A/S | Modified lysine-mimetic compounds |
WO2010056717A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
WO2011011508A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
US7951823B2 (en) | 2006-05-23 | 2011-05-31 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
WO2011143057A1 (en) | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
WO2011156246A1 (en) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
US8664212B2 (en) | 2007-04-13 | 2014-03-04 | The Regents Of The University Of Michigan | Diazo bicyclic Smac mimetics and the uses thereof |
US9018175B2 (en) | 2009-12-18 | 2015-04-28 | Takeda Gmbh | 3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives |
CN110981936A (zh) * | 2018-09-28 | 2020-04-10 | 北京京东方技术开发有限公司 | 类肽化合物及其制备方法、寡聚物、药物组合物和试剂盒 |
US11324799B2 (en) | 2017-05-05 | 2022-05-10 | Zealand Pharma A/S | Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease |
US11453621B2 (en) | 2015-12-11 | 2022-09-27 | Electrophoretics Limited | Isobaric mass labels having n',n'-dimeihyl piperazine-2-carboxylic acid reporter moieties |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2462200A1 (en) * | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
EP1469875A1 (en) | 2002-01-29 | 2004-10-27 | Wyeth | Compositions and methods for modulating connexin hemichannels |
US7968548B2 (en) * | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
EP1688161A1 (en) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
CN101151248B (zh) | 2005-01-26 | 2012-06-20 | 阿勒根公司 | 具有镇痛活性和/或免疫刺激物活性的3-芳基-3-羟基-2-氨基丙酸酰胺类、3-杂芳基-3-羟基-2-氨基丙酸酰胺类以及相关化合物 |
US20070129444A1 (en) * | 2005-12-06 | 2007-06-07 | Mallinckrodt Inc. | Novel weight reduction composition and uses thereof |
AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
WO2008085608A1 (en) * | 2007-01-10 | 2008-07-17 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
US20090076029A1 (en) * | 2007-06-01 | 2009-03-19 | Palatin Technologies, Inc. | Compounds and Methods for Treating Obesity |
US20090081197A1 (en) * | 2007-06-01 | 2009-03-26 | Palatin Technologies, Inc. | Methods for Selection of Melanocortin Receptor-Specific Agents for Treatment of Obesity |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP2242745A1 (de) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
KR101430627B1 (ko) | 2008-05-13 | 2014-08-14 | 유니버시티 오브 캔사스 | 금속 추출 펩타이드(map) 태그 및 관련된 방법 |
UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
CA2771278A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
NZ599774A (en) * | 2009-11-23 | 2014-11-28 | Palatin Technologies Inc | Melanocortin-1 receptor-specific cyclic peptides |
CA2815855C (en) | 2010-11-01 | 2016-02-02 | Rfs Pharma, Llc | Novel specific hcv ns3 protease inhibitors |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
MX339762B (es) * | 2011-09-28 | 2016-05-27 | Univ Autonoma Del Estado De Morelos | Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen. |
US9402877B2 (en) | 2011-11-04 | 2016-08-02 | Xion Pharmaceuticals Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
US9040479B2 (en) | 2012-01-12 | 2015-05-26 | Cocrystal Pharma, Inc. | HCV NS3 protease inhibitors |
WO2013181461A2 (en) | 2012-06-01 | 2013-12-05 | University Of Kansas | Metal abstraction peptide with superoxide dismutase activity |
WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5331573A (en) * | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
US5856326A (en) * | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6027711A (en) * | 1995-06-07 | 2000-02-22 | Rhomed Incorporated | Structurally determined metallo-constructs and applications |
WO2001013112A1 (en) * | 1999-08-12 | 2001-02-22 | Palatin Technologies, Inc. | Melanocortin metallopeptide constructs, combinatorial libraries and applications |
Family Cites Families (179)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4148923A (en) * | 1972-05-31 | 1979-04-10 | Synthelabo | 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity |
US4626549A (en) * | 1974-01-10 | 1986-12-02 | Eli Lilly And Company | Treatment of obesity with aryloxyphenylpropylamines |
IT1157365B (it) * | 1977-10-24 | 1987-02-11 | Sandoz Ag | Medicamenti per trattare l'obesita' o ridurre il peso del corpo |
US4711957A (en) | 1979-07-13 | 1987-12-08 | The B. F. Goodrich Company | Synthesis of 2-keto-1,4-diazacycloalkanes |
US4434454A (en) * | 1981-02-06 | 1984-02-28 | Day J Michael | Active lighting system including light control keyboard |
US4766125A (en) | 1981-06-23 | 1988-08-23 | Janssen Pharmaceutica N.V. | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia |
US4680289A (en) * | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
GB8607312D0 (en) * | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
US4968684A (en) | 1987-04-01 | 1990-11-06 | Janssen Pharmaceutica N.V. | Method of improving sleep |
DK247789A (da) | 1988-05-23 | 1989-11-24 | Glaxo Group Ltd | Piperazinderivater |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US4997836A (en) | 1988-11-11 | 1991-03-05 | Takeda Chemical Industries, Ltd. | Trisubstituted piperazine compounds, their production and use |
US5120713A (en) * | 1990-09-10 | 1992-06-09 | Applied Research Systems Ars Holding N.V. | Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide |
US5292726A (en) | 1991-05-22 | 1994-03-08 | Merck & Co., Inc. | N,N-diacylpiperazines |
SE9202266D0 (sv) | 1992-07-31 | 1992-07-31 | Kabi Pharmacia Ab | Novel piperazine carboxamides |
US5432691A (en) * | 1992-11-18 | 1995-07-11 | Vari-Lite, Inc. | Automated truss module with deployment mechanism |
US5344830A (en) | 1992-12-10 | 1994-09-06 | Merck & Co., Inc. | N,N-diacylpiperazine tachykinin antagonists |
PT690843E (pt) * | 1993-03-25 | 2001-01-31 | Upjohn Co | Derivados de indolo substituidos com formilo ou ciano possuindo actividade dopaminergica |
HUT70045A (en) | 1993-06-17 | 1995-09-28 | Takeda Chemical Industries Ltd | 2-piperazinone derivatives parmaceutical compositions containing them and process for producing them |
WO1995000497A1 (en) | 1993-06-18 | 1995-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5348955A (en) | 1993-06-22 | 1994-09-20 | Merck & Co., Inc. | N,N-diacylpiperazines |
US5494919A (en) | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5721251A (en) | 1993-12-10 | 1998-02-24 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
US5721250A (en) | 1993-12-23 | 1998-02-24 | Merck & Co. Inc. | Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
US5599809A (en) | 1994-09-29 | 1997-02-04 | Merck & Co., Inc. | Method for improving reproductive efficiency in farm animals |
US6245764B1 (en) | 1995-03-24 | 2001-06-12 | Molecumetics Ltd. | β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins |
KR100414321B1 (ko) | 1995-04-13 | 2004-02-18 | 아벤티스 파마슈티칼스 인크. | 타치키닌수용체길항활성을갖는신규한치환된피페라진유도체 |
US5935963A (en) | 1995-04-26 | 1999-08-10 | Takeda Chemical Industries, Ltd | Piperazinones, their production and use |
US5719156A (en) | 1995-05-02 | 1998-02-17 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
DE19518988A1 (de) * | 1995-05-29 | 1996-12-05 | Basf Ag | Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit |
EP0828754B1 (en) | 1995-05-29 | 2005-02-02 | Pfizer Inc. | Dipeptides which promote release of growth hormone |
WO2002064091A2 (en) | 2001-02-13 | 2002-08-22 | Palatin Technologies, Inc. | Melanocortin metallopeptides for treatment of sexual dysfunction |
US5891418A (en) | 1995-06-07 | 1999-04-06 | Rhomed Incorporated | Peptide-metal ion pharmaceutical constructs and applications |
US6184223B1 (en) | 1995-10-27 | 2001-02-06 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
US5753653A (en) | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
US6087357A (en) | 1995-12-18 | 2000-07-11 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives as tachykinin antagonists |
US6303611B1 (en) | 1996-03-08 | 2001-10-16 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
US6239154B1 (en) | 1996-03-08 | 2001-05-29 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
US5763445A (en) | 1996-03-08 | 1998-06-09 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
GB9612276D0 (en) * | 1996-06-12 | 1996-08-14 | Merck & Co Inc | 4-Spiroindoline piperidines promote release of growth hormone |
US5804578A (en) * | 1996-04-03 | 1998-09-08 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5880128A (en) | 1996-05-08 | 1999-03-09 | Schering Corporation | Carbonyl piperazinyl and piperidinyl compounds |
GB9611461D0 (en) * | 1996-06-01 | 1996-08-07 | Ciba Geigy Ag | New compounds |
US6331285B1 (en) | 1996-06-05 | 2001-12-18 | Palatin Technologies, Inc. | Structurally determined cyclic metallo-constructs and applications |
EP0852117A4 (en) * | 1996-06-12 | 1999-02-03 | Kyowa Hakko Kogyo Kk | IMPROVEMENT OF LIPID METABOLISM |
WO1998010653A1 (en) | 1996-09-13 | 1998-03-19 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone |
US5877182A (en) * | 1996-09-13 | 1999-03-02 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
WO1998017625A1 (fr) * | 1996-10-22 | 1998-04-30 | Daiichi Pharmaceutical Co., Ltd. | Nouveaux remedes pour des maladies infectieuses |
US5734054A (en) | 1996-11-05 | 1998-03-31 | Pharmacopeia, Inc. | Hydroxy-amino acid amides |
US5965565A (en) * | 1996-12-12 | 1999-10-12 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
EP0948489A1 (en) | 1996-12-17 | 1999-10-13 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine compounds as inhibitors of mmp or tnf |
AU739469B2 (en) | 1996-12-20 | 2001-10-11 | Alza Corporation | Gel composition and methods |
JP2001523245A (ja) * | 1997-04-24 | 2001-11-20 | メルク シヤープ エンド ドーム リミテツド | 肥満を治療するためのnk−1受容体拮抗薬およびssriの使用 |
CZ296017B6 (cs) | 1997-05-27 | 2005-12-14 | Direct-Haler A/S | Zařízení pro aplikaci práškové či částicové substance |
US6207665B1 (en) | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
US5968938A (en) | 1997-06-18 | 1999-10-19 | Merck & Co., Inc. | Piperazine oxytocin receptor antagonists |
US6287587B2 (en) | 1997-07-15 | 2001-09-11 | Takeda Chemical Industries, Ltd. | Process for producing sustained-release preparation by in-water drying |
US6211626B1 (en) | 1997-08-26 | 2001-04-03 | Color Kinetics, Incorporated | Illumination components |
US6193991B1 (en) | 1997-10-29 | 2001-02-27 | Atul J. Shukla | Biodegradable delivery systems of biologically active substances |
US5892038A (en) | 1997-12-08 | 1999-04-06 | Pharmacopeia, Inc. | Hydroxy-amino acid amides |
US6084098A (en) | 1999-02-26 | 2000-07-04 | Neurogen Corporation | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands |
US6613234B2 (en) * | 1998-04-06 | 2003-09-02 | Ciphergen Biosystems, Inc. | Large pore volume composite mineral oxide beads, their preparation and their applications for adsorption and chromatography |
US6534503B1 (en) * | 1998-04-28 | 2003-03-18 | Lion Bioscience Ag | Melanocortin receptor-3 ligands to treat sexual dysfunction |
US6284735B1 (en) * | 1998-04-28 | 2001-09-04 | Lion Bioscience Ag | HP-3228 and related peptides to treat sexual dysfunction |
EP1076649A4 (en) | 1998-04-28 | 2010-06-02 | Trega Biosciences Inc | ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE |
PT1076644E (pt) * | 1998-04-29 | 2004-10-29 | Ortho Mcneil Pharm Inc | Aminotetralinas substituidas emn como ligandos para o receptor de neuropeptideoy y5 util no tratamento da obesidade e de outras perturbacoes |
PT1077941E (pt) | 1998-05-11 | 2010-07-01 | Novo Nordisk As | Compostos com propriedades de libertaão da hormona de crescimento |
US6294534B1 (en) * | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
CA2334551A1 (en) * | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
DK1100824T3 (da) * | 1998-06-30 | 2011-06-20 | Helsinn Therapeutics Us Inc | Forbindelser med væksthormonfrigivende egenskaber |
FR2780649B1 (fr) | 1998-07-06 | 2001-03-09 | Univ Paris Vii Denis Diderot | Derives de la piperazine pour l'inhibition de la replication du virus de l'immunodeficience humaine |
WO2000005373A2 (en) | 1998-07-21 | 2000-02-03 | Millenium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of body weight disorders, including obesity |
DE69925840T2 (de) | 1998-08-12 | 2006-05-04 | Pfizer Products Inc., Groton | Tace inhibitoren |
AU5722499A (en) * | 1998-09-17 | 2000-04-10 | Hopital Sainte-Justine | G protein-coupled receptor agonists or antagonists |
GB9827500D0 (en) | 1998-12-14 | 1999-02-10 | Wapharm Ab | Compounds for control of eating, growth and body weight |
US6372747B1 (en) | 1998-12-18 | 2002-04-16 | Schering Corporation | Farnesyl protein transferase inhibitors |
US6800636B2 (en) | 1998-12-18 | 2004-10-05 | Schering Corporation | Farnesyl protein transferase inhibitors |
US6432959B1 (en) | 1998-12-23 | 2002-08-13 | Schering Corporation | Inhibitors of farnesyl-protein transferase |
AR022204A1 (es) | 1999-01-08 | 2002-09-04 | Norgine Bv | Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende. |
US6294539B1 (en) | 1999-01-19 | 2001-09-25 | Advanced Syntech, Llc | Heterocyclic hydroxamic acid derivatives as MMP inhibitors |
AR022303A1 (es) * | 1999-01-22 | 2002-09-04 | Lundbeck & Co As H | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion |
ES2235836T3 (es) | 1999-03-03 | 2005-07-16 | Optinose As | Dispositivo de entrega nasal. |
US6033656A (en) * | 1999-05-04 | 2000-03-07 | Sumitomo Chemical Company, Limited | Method of preventing or alleviating mammalian obesity |
US6420369B1 (en) | 1999-05-24 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating dementia |
CA2377369A1 (en) * | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
US6469006B1 (en) | 1999-06-15 | 2002-10-22 | Bristol-Myers Squibb Company | Antiviral indoleoxoacetyl piperazine derivatives |
US6207699B1 (en) * | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
US6579968B1 (en) * | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
AU6605800A (en) | 1999-07-16 | 2001-02-05 | Trega Biosciences, Inc. | Melanocortin receptor-3 ligands to treat sexual dysfunction |
US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
EP1078632A1 (en) | 1999-08-16 | 2001-02-28 | Sanofi-Synthelabo | Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity |
US6774138B2 (en) | 1999-08-31 | 2004-08-10 | Merck & Co., Inc. | Thiazolyl(pyridyl)ethyne compounds |
US6294525B1 (en) | 1999-09-01 | 2001-09-25 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
GB9921239D0 (en) | 1999-09-08 | 1999-11-10 | Plant Bioscience Ltd | Plant resistance gene |
CA2384089A1 (en) | 1999-09-08 | 2001-03-15 | Genentech, Inc. | Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity |
WO2001021634A1 (en) | 1999-09-21 | 2001-03-29 | Lion Bioscience Ag | Benzimidazole derivatives and combinatorial libraries thereof |
WO2001021647A2 (en) | 1999-09-22 | 2001-03-29 | Genset | Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases |
US6515122B1 (en) | 1999-09-24 | 2003-02-04 | Lion Bioscience Ag | Tetracyclic benzimidazole derivatives and combinatorial libraries thereof |
US6458789B1 (en) | 1999-09-29 | 2002-10-01 | Lion Bioscience Ag | 2-aminopyridine derivatives and combinatorial libraries thereof |
EP1284728A4 (en) | 1999-10-22 | 2004-05-19 | Merck & Co Inc | MEDICINES FOR TREATING ADDICTIC ADDICTION |
US20030064921A1 (en) | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
WO2001030808A1 (en) * | 1999-10-27 | 2001-05-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor-ligand binding |
JP2001184828A (ja) * | 1999-12-21 | 2001-07-06 | Sony Corp | ライナ貼付方法及びライナ貼付装置 |
SE9904738D0 (sv) | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
DE19963234A1 (de) | 1999-12-27 | 2002-01-24 | Boehringer Ingelheim Pharma | Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
US6462046B2 (en) | 2000-01-06 | 2002-10-08 | Advanced Syntech, Llc | Heterocycle derivatives as PPAR-gamma agonists |
US6693165B2 (en) * | 2000-01-18 | 2004-02-17 | Merck & Co., Inc. | Cyclic peptides as potent and selective melanocortin-4 receptor antagonists |
EP1125579A3 (en) | 2000-01-18 | 2003-01-02 | Pfizer Products Inc. | Uses of agrp-melanocortin receptor binding modulating compounds |
GB0002059D0 (en) | 2000-01-28 | 2000-03-22 | Melacure Therapeutics Ab | Novel aromatic amines |
AU2001228681A1 (en) | 2000-01-28 | 2001-08-07 | Melacure Therapeutics Ab | Novel aromatic amines and amides acting on the melanocortin receptors |
MXPA02007289A (es) * | 2000-01-28 | 2003-09-22 | Melacure Therapeutics Ab | Agonistas y antagonistas novedosos de receptores de melanocortina. |
US6451798B2 (en) | 2000-02-22 | 2002-09-17 | Cv Therapeutics, Inc. | Substituted alkyl piperazine derivatives |
WO2001070347A1 (en) | 2000-03-17 | 2001-09-27 | Fit Express, Inc. | Golf swing conditioner |
EP1136071A3 (en) * | 2000-03-22 | 2003-03-26 | Pfizer Products Inc. | Use of glycogen phosphorylase inhibitors |
CA2403631A1 (en) * | 2000-03-23 | 2001-09-27 | Brenda L. Palucki | Spiropiperidine derivatives as melanocortin receptor agonists |
CA2403686C (en) * | 2000-03-23 | 2010-01-26 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
EA006079B1 (ru) | 2000-03-31 | 2005-08-25 | Пфайзер Продактс Инк. | Новые пиперазиновые производные |
AU2001264977B2 (en) * | 2000-05-30 | 2005-04-14 | Merck & Co., Inc. | Melanocortin receptor agonists |
US6949552B2 (en) | 2000-06-27 | 2005-09-27 | Taisho Pharmaceutical Co., Ltd. | Remedial agent for anxiety neurosis or depression and piperazine derivative |
EA200201119A1 (ru) * | 2000-06-28 | 2003-06-26 | Пфайзер Продактс Инк. | Лиганды меланокортиновых рецепторов |
EP1366030A2 (en) | 2000-07-06 | 2003-12-03 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
US20020032238A1 (en) | 2000-07-08 | 2002-03-14 | Henning Priepke | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments |
US6191117B1 (en) * | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
GB0019359D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
BR0113637A (pt) | 2000-08-30 | 2004-02-25 | Hoffmann La Roche | Composto, processo para a preparação desse composto, composição farmacêutica que compreende o mesmo, utilização do composto, processo para o tratamento e/ou profilaxia de enfermidade que estão associadas com a atividade de receptor melanocortin-4 |
US20020183316A1 (en) | 2000-10-27 | 2002-12-05 | Kevin Pan | Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders |
KR100394083B1 (ko) | 2000-12-04 | 2003-08-06 | 학교법인 성신학원 | 도파민 d3 및 d4 수용체의 선택적 활성을 지닌 신규4,5-디히드로이소옥사졸릴알킬피페라진 유도체와, 이의제조방법 |
US6612805B2 (en) | 2000-12-05 | 2003-09-02 | Emu Unterwasserpumpen Gmbh | Hydrodynamic machine |
AU2002220977A1 (en) | 2000-12-15 | 2002-06-24 | Pfizer Inc. | Treatment of male sexual dysfunction |
US7186715B2 (en) | 2001-01-08 | 2007-03-06 | Eli Lilly And Company | Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
ATE341327T1 (de) | 2001-02-28 | 2006-10-15 | Merck & Co Inc | Acylierte piperidin-derivate als melanocortin-4- rezeptor-agonisten |
ATE430565T1 (de) | 2001-02-28 | 2009-05-15 | Merck & Co Inc | Acylierte piperidinderivate als melanocortin-4- rezeptoragonisten |
EP1236723A1 (en) | 2001-03-01 | 2002-09-04 | Pfizer Products Inc. | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof |
HUP0303484A2 (hu) | 2001-03-02 | 2004-01-28 | Bristol-Myers Squibb Company | Melanokortin receptor modulátoraiként hasznos vegyületek és a vegyületeket tartalmazó gyógyszerkészítmények |
WO2002069905A2 (en) * | 2001-03-02 | 2002-09-12 | Bristol-Myers Squibb Company | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
US6660858B2 (en) | 2001-03-28 | 2003-12-09 | Lion Bioscience Ag | 2-aminobenzoxazole derivatives and combinatorial libraries thereof |
GB0107751D0 (en) | 2001-03-28 | 2001-05-16 | Pfizer Ltd | Pharmaceutically active compounds |
EP1385823B1 (en) * | 2001-04-09 | 2006-12-13 | Chiron Corporation | Guanidino compounds as melanocortin-4 receptor (mc4-r) agonists |
US6911447B2 (en) * | 2001-04-25 | 2005-06-28 | The Procter & Gamble Company | Melanocortin receptor ligands |
CN1329382C (zh) | 2001-05-11 | 2007-08-01 | 比奥维特罗姆股份公司 | 治疗肥胖、ⅱ型糖尿病和cns-疾病的芳基磺酰胺化合物 |
AU2002342244B2 (en) | 2001-05-15 | 2005-06-16 | F. Hoffmann-La Roche Ag | Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes |
KR20040007565A (ko) | 2001-05-15 | 2004-01-24 | 다이쇼 세이야꾸 가부시끼가이샤 | 아르기닌 유도체 |
US6593362B2 (en) | 2001-05-21 | 2003-07-15 | Guilford Pharmaceuticals Inc. | Non-peptidic cyclophilin binding compounds and their use |
CZ20033455A3 (en) | 2001-06-20 | 2004-06-16 | Pfizer Products Inc. | Novel sulfonic acid derivatives |
US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
IL159797A0 (en) | 2001-07-11 | 2004-06-20 | Palatin Technologies Inc | Linear and cyclic melanocortin receptor-specific peptides |
US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
GB0118479D0 (en) | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
GB0119172D0 (en) | 2001-08-06 | 2001-09-26 | Melacure Therapeutics Ab | Phenyl pyrrole derivatives |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US7354923B2 (en) | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
CA2462200A1 (en) | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7732451B2 (en) | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
HUP0202719A3 (en) * | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
EP1421084B1 (en) | 2001-08-28 | 2008-05-14 | Schering Corporation | Polycyclic guanine phosphodiesterase v inhibitors |
AU2002326948A1 (en) | 2001-09-18 | 2003-04-01 | Bristol-Myers Squibb Company | Piperizinones as modulators of chemokine receptor activity |
WO2003027239A2 (en) | 2001-09-26 | 2003-04-03 | Merck & Co., Inc. | Melanin-concentrating hormone receptor antagonist binding protein |
EP1465867A1 (en) | 2001-10-09 | 2004-10-13 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
CZ2004519A3 (cs) | 2001-10-22 | 2004-12-15 | Pfizer Products Inc. | Deriváty piperazinu s účinky antagonisty receptoru CCR1 |
US7319107B2 (en) | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
NZ532883A (en) | 2001-11-08 | 2007-09-28 | Ortho Mcneil Pharm Inc | Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators |
EP1451156A4 (en) | 2001-11-27 | 2005-05-25 | Merck & Co Inc | 4-AMINOQUINOLINE COMPOUNDS |
MXPA04005999A (es) | 2001-12-21 | 2005-07-13 | Taisho Pharma Co Ltd | Derivado de piperazina. |
WO2003055477A1 (en) | 2001-12-21 | 2003-07-10 | 7Tm Pharma A/S | Method for the treatment of mc receptor related disorders with a chelate and/or a chelator |
WO2003061660A1 (en) | 2002-01-23 | 2003-07-31 | Eli Lilly And Company | Melanocortin receptor agonists |
US20030207814A1 (en) | 2002-02-04 | 2003-11-06 | Chiron Corporation | Novel guanidinyl derivatives |
US20030195187A1 (en) | 2002-02-04 | 2003-10-16 | Chiron Corporation | Guanidino compounds |
WO2003072056A2 (en) | 2002-02-25 | 2003-09-04 | Chiron Corporation | Intranasal administration of mc4-r agonists |
WO2003094918A1 (en) | 2002-05-10 | 2003-11-20 | Neurocrine Biosciences, Inc. | Substituted piperazine as melanocortin receptors ligands |
AR043434A1 (es) | 2003-03-03 | 2005-07-27 | Merck & Co Inc | Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
TW200609219A (en) | 2004-06-17 | 2006-03-16 | Neurogen Corp | Aryl-substituted piperazine derivatives |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
US20090076029A1 (en) | 2007-06-01 | 2009-03-19 | Palatin Technologies, Inc. | Compounds and Methods for Treating Obesity |
-
2002
- 2002-08-12 CA CA002462200A patent/CA2462200A1/en not_active Abandoned
- 2002-08-12 AU AU2002331064A patent/AU2002331064B2/en not_active Ceased
- 2002-08-12 EP EP02768507A patent/EP1425029A4/en not_active Withdrawn
- 2002-08-12 WO PCT/US2002/025574 patent/WO2003013571A1/en active Application Filing
- 2002-08-12 JP JP2003518577A patent/JP2005504043A/ja active Pending
-
2004
- 2004-01-21 US US10/761,889 patent/US7326707B2/en not_active Expired - Fee Related
- 2004-02-10 US US10/776,657 patent/US7189755B2/en not_active Expired - Fee Related
- 2004-02-10 US US10/776,419 patent/US7807678B2/en not_active Expired - Fee Related
-
2007
- 2007-03-01 US US11/680,932 patent/US7601753B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5331573A (en) * | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
US5579250A (en) * | 1990-12-14 | 1996-11-26 | Balaji; Vitukudi N. | Method of rational drug design based on AB initio computer simulation of conformational features of peptides |
US5856326A (en) * | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6027711A (en) * | 1995-06-07 | 2000-02-22 | Rhomed Incorporated | Structurally determined metallo-constructs and applications |
WO2001013112A1 (en) * | 1999-08-12 | 2001-02-22 | Palatin Technologies, Inc. | Melanocortin metallopeptide constructs, combinatorial libraries and applications |
Non-Patent Citations (6)
Title |
---|
CORNILLE ET AL.: "Anodic amide oxidations: conformationally restricted peptide building blocks from the direct oxidation of dipeptides", TET. LETTERS, vol. 35, no. 38, 1994, pages 6989 - 6922, XP002959236 * |
DIMAIO ET AL.: "Synthesis of chiral piperazin-2-ones as model peptidomimetics", J. CHEM. SOC. PERKIN TRANS. I, 1989, pages 1687 - 1689, XP002959604 * |
HRUBY ET AL.: "Molecular organization of receptors", ANN. NY ACAD. SCI., vol. 757, 1995, pages 7 - 22, XP002959610 * |
JONATHAN A.; ELIMAN ET AL., J. AM. CHEM. SOC., vol. 117, 1995, pages 3306 - 3307 |
MOORE ET AL.: "A rapid screening system to determine drug affinities for the intestinal dipeptide transporter 2: affinities of ACE inhibitors", INT. J. PHARMACEUTICS, vol. 210, 2000, pages 29 - 44, XP002959237 * |
See also references of EP1425029A4 |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7026335B2 (en) | 2002-04-30 | 2006-04-11 | The Procter & Gamble Co. | Melanocortin receptor ligands |
US7132539B2 (en) | 2002-10-23 | 2006-11-07 | The Procter & Gamble Company | Melanocortin receptor ligands |
EA012502B1 (ru) * | 2003-05-01 | 2009-10-30 | Палатин Текнолоджиз, Инк. | Соединения, специфичные к меланокортиновым рецепторам |
WO2004098602A1 (en) * | 2003-05-01 | 2004-11-18 | Palatin Technologies, Inc. | Melanocortin receptor-specific compounds |
WO2005102340A1 (en) * | 2003-05-30 | 2005-11-03 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
WO2005079574A1 (en) * | 2004-01-21 | 2005-09-01 | Palatin Technologies, Inc. | Bicyclic melanocorin-specific compounds |
US8431540B2 (en) | 2005-12-23 | 2013-04-30 | Zealand Pharma A/S | Modified lysine-mimetic compounds |
US7622496B2 (en) | 2005-12-23 | 2009-11-24 | Zealand Pharma A/S | Modified lysine-mimetic compounds |
US7951823B2 (en) | 2006-05-23 | 2011-05-31 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
WO2008090357A2 (en) * | 2007-01-24 | 2008-07-31 | Palatin Technologies, Inc. | N, n; -substituted piperazines binding to melanocortin receptor |
WO2008090357A3 (en) * | 2007-01-24 | 2008-10-23 | Palatin Technologies Inc | N, n; -substituted piperazines binding to melanocortin receptor |
US8664212B2 (en) | 2007-04-13 | 2014-03-04 | The Regents Of The University Of Michigan | Diazo bicyclic Smac mimetics and the uses thereof |
WO2009105823A1 (en) | 2008-02-29 | 2009-09-03 | Mimetica Pty Ltd | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
EP2257534A1 (en) * | 2008-02-29 | 2010-12-08 | Mimetica Pty Limited | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
EP2257533A1 (en) * | 2008-02-29 | 2010-12-08 | Mimetica Pty Limited | 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
WO2009105825A1 (en) | 2008-02-29 | 2009-09-03 | Mimetica Pty Ltd | 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
EP2257534A4 (en) * | 2008-02-29 | 2011-05-04 | Mimetica Pty Ltd | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
EP2257533A4 (en) * | 2008-02-29 | 2011-05-11 | Mimetica Pty Ltd | 3-SUBSTITUTED-1,4-DIAZEPAN-2-ONE ANTAGONISTS OF MELANOCORTIN RECEPTOR 5 |
US8440653B2 (en) | 2008-02-29 | 2013-05-14 | Mimetica Pty Ltd | 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
WO2010056717A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
WO2011011508A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
US9018175B2 (en) | 2009-12-18 | 2015-04-28 | Takeda Gmbh | 3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives |
WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
WO2011143057A1 (en) | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
WO2011156246A1 (en) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
US11453621B2 (en) | 2015-12-11 | 2022-09-27 | Electrophoretics Limited | Isobaric mass labels having n',n'-dimeihyl piperazine-2-carboxylic acid reporter moieties |
US11324799B2 (en) | 2017-05-05 | 2022-05-10 | Zealand Pharma A/S | Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease |
CN110981936A (zh) * | 2018-09-28 | 2020-04-10 | 北京京东方技术开发有限公司 | 类肽化合物及其制备方法、寡聚物、药物组合物和试剂盒 |
CN110981936B (zh) * | 2018-09-28 | 2021-10-12 | 北京京东方技术开发有限公司 | 类肽化合物及其制备方法、寡聚物、药物组合物和试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
US20040167201A1 (en) | 2004-08-26 |
US20040171520A1 (en) | 2004-09-02 |
EP1425029A4 (en) | 2006-06-07 |
US7189755B2 (en) | 2007-03-13 |
US7601753B2 (en) | 2009-10-13 |
US20040152134A1 (en) | 2004-08-05 |
US7326707B2 (en) | 2008-02-05 |
EP1425029A1 (en) | 2004-06-09 |
US20070155670A1 (en) | 2007-07-05 |
US7807678B2 (en) | 2010-10-05 |
CA2462200A1 (en) | 2003-02-20 |
AU2002331064B2 (en) | 2007-08-23 |
JP2005504043A (ja) | 2005-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002331064B2 (en) | Peptidomimetics of biologically active metallopeptides | |
AU2002331064A1 (en) | Peptidomimetics of biologically active metallopeptides | |
US7964601B2 (en) | Melanocortin receptor-specific compounds | |
AU2002322466B2 (en) | Linear and cyclic melanocortin receptor-specific peptides | |
Williams et al. | 1-(((7, 7-Dimethyl-2 (S)-(2 (S)-amino-4-(methylsulfonyl) butyramido) bicyclo [2.2. 1] heptan-1 (S)-yl) methyl) sulfonyl)-4-(2-methylphenyl) piperazine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor | |
Doedens et al. | Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies | |
Rivera et al. | A multicomponent conjugation strategy to unique N‐steroidal peptides: first evidence of the steroidal nucleus as a β‐turn inducer in acyclic peptides | |
Sun et al. | Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics | |
US7354923B2 (en) | Piperazine melanocortin-specific compounds | |
Creighton et al. | Design, synthesis, and conformational analysis of eight-membered cyclic peptidomimetics prepared using ring closing metathesis | |
Mollica et al. | New potent biphalin analogues containing p-fluoro-L-phenylalanine at the 4, 4′ positions and non-hydrazine linkers | |
Cain et al. | Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the melanocortin receptors | |
US7385025B2 (en) | Metallopeptide compounds | |
US20060240481A1 (en) | Melanocortin Metallopeptode Combinatorial Libraries and Applications | |
Ujjainwalla et al. | Small molecule ligands of the human melanocortin-4 receptor | |
Fang et al. | Design, synthesis, and opioid activity of arodyn analogs cyclized by ring-closing metathesis involving Tyr (allyl) | |
Gomez‐Paloma et al. | Design and synthesis of cyclopeptide analogues of the potent histone deacetylase inhibitor FR235222 | |
Mollica et al. | Synthesis and biological evaluation of new biphalin analogues with non-hydrazine linkers | |
Monga et al. | Synthesis, receptor binding, and CNS pharmacological studies of new thyrotropin‐releasing hormone (TRH) analogues | |
WO2005102340A1 (en) | Piperazine melanocortin-specific compounds | |
Fry et al. | Utilizing peptide structures as keys for unlocking challenging targets | |
ZA200509683B (en) | Melanocortin receptor-specific compounds | |
Bélec et al. | The influence of steric interactions on the conformation and biology of oxytocin. Synthesis and analysis of penicillamine6‐oxytocin and penicillamine6‐5‐tert‐butylproline7‐oxytocin analogs | |
Hameed et al. | Recent Advances in the Design and Synthesis of Cyclic Peptidomimetics | |
AU2005201166A1 (en) | Melanocortin metallopeptide constructs, combinatorial libraries and applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10762079 Country of ref document: US Ref document number: 10761889 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003518577 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10776657 Country of ref document: US Ref document number: 10776419 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002768507 Country of ref document: EP Ref document number: 2002331064 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2462200 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2002768507 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |